Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Daré Bioscience reported second quarter 2026 results and highlighted a shift toward commercialization in women’s health. The company launched Flora Sync LF5, its first directly commercialized product, which began generating revenue in July, and is preparing for national dispensing of DARE to PLAY Sildenafil Cream with initial revenue expected in the third quarter of 2026. The pipeline advanced with positive interim Phase 3 Ovaprene results and initiation of the DARE-HPV Phase 2 study, supported by significant grant funding recorded as contra-R&D expense.
For the quarter ended June 30, 2026, total revenue was $187,546 versus $(21,172) a year earlier, while net loss narrowed to $2,982,773 from $4,016,483. Cash and cash equivalents were $12.6 million, down from $24.7 million at December 31, 2025. Working capital moved to a $0.2 million deficit and stockholders’ equity to a $0.6 million deficit, reflecting balance sheet pressure as the company invests in commercialization. Risk disclosures emphasize the need for additional capital to continue as a going concern and the possibility of Nasdaq Capital Market suspension or delisting.
Daré Bioscience, Inc. reports that its women’s health business remains focused on developing and commercializing products across contraception, sexual health, vaginal health and other indications, while shifting more resources toward commercial execution, including Section 503B outsourcing and consumer health channels.
For the six months ended June 30, 2026, total revenue was $340,001, primarily from research and development services and royalty revenue. Operating expenses were $5.7 million, leading to a net loss of $5,982,662, compared with a loss of $8,394,790 in 2025. Operating cash outflow was $12,295,690. Cash and cash equivalents were $12,617,594, all from grant funding, and deferred grant funding liability was $14,954,724. Stockholders’ equity turned to a deficit of $560,100, with an accumulated deficit of $194,671,566. The company discloses substantial doubt about its ability to continue as a going concern within 12 months without additional capital and is pursuing options including equity sales (Lincoln Park equity line and a Regulation A preferred stock and warrant offering) and other financings.
Daré Bioscience, Inc. furnished a corporate presentation dated July 24, 2026 as Exhibit 99.1 under Regulation FD. The company intends to use this presentation in meetings with securities market participants and others beginning July 24, 2026.
Daré Bioscience plans to make the presentation available in the Investors section of its website, on the page titled “Presentations, Events & Webcasts” under “Presentations.” The related information is being furnished, not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other Exchange Act or Securities Act filings except where specifically referenced.
Daré Bioscience, Inc. reports that Nasdaq’s Listing Qualifications Staff notified it on July 13, 2026 that its common stock no longer complies with Nasdaq Listing Rule 5550(b). The company’s Form 10-Q for the period ended March 31, 2026 reported stockholders’ equity of less than $2.5 million, and as of that date it also did not meet alternative requirements of $35 million market value of listed securities or $500,000 in net income from continuing operations.
The company plans to timely request a hearing before a Nasdaq Hearing Panel, which will stay any suspension or delisting at least until the Panel issues its decision and any extension period expires. The company cautions there is no assurance an extension will be granted, that compliance will be regained within any extension, or that its common stock will remain listed on Nasdaq.
Daré Bioscience, Inc. furnished a new corporate presentation dated July 13, 2026 as part of a Regulation FD communication. The presentation is being used in meetings with securities market participants and others beginning on that date and will be accessible through the Investors section of the company’s website.
The information in the presentation and in this Regulation FD communication is designated as furnished, not filed under the Securities Exchange Act of 1934, which limits its exposure to certain statutory liabilities and incorporation by reference into other securities law filings unless specifically referenced.
Grossman Jessica D. reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience director Jessica D. Grossman received an equity grant instead of cash fees for her board service. She was awarded 26,066 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share.
Each restricted stock unit represents a right to receive one Dare Bioscience share when it vests. All 26,066 units vest on January 4, 2027, and this grant brings her directly held position from this award to 26,066 shares.
Kelley Susan L. reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience, Inc. reported that director Susan L. Kelley received a grant of 23,696 shares of common stock in the form of restricted stock units (RSUs). These RSUs were granted in lieu of cash compensation for her service on the board and its committees.
Each RSU represents a right to receive one share of Dare Bioscience common stock when vested, and the RSUs vest on January 4, 2027. Following this award, Kelley’s reported direct holdings total 23,696 shares.
Dare Bioscience director Gregory W. Matz received a grant of 30,805 shares of common stock in the form of restricted stock units as compensation for serving on the company’s board and its committees. Each RSU converts into one share when it vests on January 4, 2027. After this award, he holds 30,847 shares directly.
RASTETTER WILLIAM H reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience director William H. Rastetter received an equity grant of 38,862 restricted stock units (RSUs). The RSUs were granted in lieu of cash compensation for his service on the board of directors and its committees, at a stated price of $0.00 per share. Each RSU represents a contingent right to receive one share of common stock upon vesting, which occurs on January 4, 2027. Following this grant, he directly holds 39,721 shares of Dare Bioscience common stock.
Steele Robin Joan reported acquisition or exercise transactions in this Form 4 filing.
Dare Bioscience director Robin Joan Steele received an equity grant instead of cash fees for board service. She was awarded 26,540 restricted stock units, each representing one share of common stock when vested, at a stated price of $0.00 per unit. Following this grant, she directly holds 47,055 shares, including the new RSUs. The RSUs vest on January 4, 2027, aligning her compensation more closely with Dare Bioscience’s long-term share performance.